General Information:

Id: 3,503 (click here to show other Interactions for entry)
Diseases: Diabetes mellitus, type II - [OMIM]
Insulin resistance
Mus musculus
PPARalpha-/- mouse
Reference: Makowski L et al.(2009) Metabolic profiling of PPARalpha-/- mice reveals defects in carnitine and amino acid homeostasis that are partially reversed by oral carnitine supplementation FASEB J. 23: 586-604 [PMID: 18945875]

Interaction Information:

Comment In the fed state, most fatty acid-derived acylcarnitine species were present at similar levels in wild-type compared to the knockout mice. Notable exceptions included acetylcarnitine (C2) and beta-OH-butyrylcarnitine (C4OH, a strong marker of beta-oxidation and ketone metabolism), both of which were markedly decreased in plasma, liver, and skeletal muscle of PPARalpha -/- mice regardless of feeding status. Succinylcarnitine (C4DC), which arises from the TCA cycle intermediate succinyl-CoA, was reduced in plasma and liver of PPARalpha -/-mice, independent of condition. Skeletal muscle concentrations of this metabolite were also low in PPARalpha -/- compared to wild-type mice, but only in the fasted state.
Formal Description
Interaction-ID: 32525



affects_quantity of

drug/chemical compound


in blood plasma, in liver, in skeletal muscle
Drugbank entries Show/Hide entries for PPARA